... May 20
Latest pharma news update... Sep 29
Latest Pharma News Update... Aug 23
According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ... Jun 25
With the approval of Pradaxa, a blood-clotting medicine, pediatric patients have a good therapeutic option to treat and prevent potentially deadly blood clots.... Jun 22
Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name - Tiogiva in UK ... Jun 15
The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type ... Jan 07
Glenmark has received tentative approval by the United States Food & Drug Administration for Dabigatran Etexilate Capsules, the generic version of Pradaxa 1 Capsules... Dec 21
... Nov 19
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
Approximately 100 hospitalized volunteers will be assigned to each study arm with each of the study sites testing no more than three investigational treatments at ... Oct 14
Manufacturing agreement for Autologous T-Cell Receptor-Based Cell Therapy... Sep 24
Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
The PetPro Tele+ platform offers setup in minutes to enable virtual veterinary visits ... May 19
BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany. ... May 18
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
Boehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim’s actively recruiting studies conducted at global ... Feb 20
Boehringer Ingelheim's pan-KRAS program promises preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA... Oct 31
New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ... Sep 20
-Advertisements-
Friday, May 17, 2024
.jpg)
